Long-Term Effects of Hearing Aids on Hearing Ability in Patients with Sensorineural Hearing Loss

2021 ◽  
Author(s):  
Anurag R. Goel ◽  
Haley A. Bruce ◽  
Nicholas Williams ◽  
George Alexiades
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Hearing Aids ◽  
Pure Tone ◽  
Likelihood Estimation ◽  
Sensorineural Hearing ◽  
Long Term Effects ◽  
Pure Tone Average ◽  
Hearing Ability

Abstract Background A frequent concern surrounding amplification with hearing aids for patients with sensorineural hearing loss is whether these devices negatively affect hearing ability. To date, there have been few studies examining the long-term effects of amplification on audiometric outcomes in adults. Purpose In the present study, we examined how hearing aids affect standard audiometric outcomes over long-term periods of follow-up. Research Design We retrospectively collected audiometric data in adults with sensorineural hearing loss, constructing a model of long-term outcomes. Study Sample This retrospective cohort study included 802 ears from 401 adult patients with bilateral sensorineural hearing loss eligible for amplification with hearing aids at a single institution. Intervention Of the eligible patients, 88 were aided bilaterally, and 313 were unaided. Data Collection and Analysis We examined the standard three-frequency pure-tone average (PTA3-Freq), a novel extended pure-tone average (PTAExt), and word recognition score (WRS) per-ear at each encounter. We then modeled the association between the use of hearing aids for 5 years and these audiometric outcomes using targeted maximum likelihood estimation. Results In comparing aided and unaided ears at the end of 5 years, there were discernible effects for all measurements. The PTA3-Freq was 5 dB greater in aided ears (95% CI: 1.37–8.64, p = 0.007), WRS was 4.5 percentage points lower in aided ears (95% CI: −9.14 to 0.15, p = 0.058), and PTAExt was 5 dB greater in aided ears (95% CI: 2.18–7.82, p < 0.001), adjusting for measured confounders. Conclusion Our analysis revealed discernible effects of 5 years of hearing aid use on hearing ability, specifically as measured by the PTA3-Freq, novel PTAExt, and WRS, suggesting a greater decline in hearing ability in patients using hearing aids. Future studies are needed to examine these effects between treatment groups over longer periods of time and in more heterogeneous populations to improve clinical practice guidelines and safety of both prescriptive fitting nonprescriptive amplification.

Otologics Fully Implantable Hearing Device Phase II Results

2008 ◽  
Vol 139 (2_suppl) ◽  
pp. P57-P57
Author(s):  
Drew M Horlbeck ◽  
Herman A Jenkins ◽  
Ben J Balough ◽  
Michael E Hoffer
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Phase Ii ◽  
Hearing Aids ◽  
Repeated Measures ◽  
Pure Tone ◽  
Sound Field ◽  
Sensorineural Hearing ◽  
Significant Difference ◽  
Hearing Device

Objective The efficacy of the Otologics Fully Implantable Hearing Device (MET) was assessed in adult patients with bilateral moderate to severe sensorineural hearing loss. Methods Surgical insertion of this totally implanted system was identical to the Phase I study. A repeated-measures within-subjects design assessed aided sound field thresholds and speech performances with the subject's own, appropriately fit, walk-in hearing aid(s) and the Otologics Fully Implantable Hearing Device. Results Six- and 12-month Phase II data will be presented. Ten patients were implanted and activated as part Phase II clinical trial. Three patients were lost to long term follow-up due to two coil failures and one ossicular abnormality preventing proper device placement. No significant differences between preoperative (AC = 59 dB, BC = 55 dB) and postoperative (AC = 61 dB, BC = 54 dB) unaided pure tone averages were noted (p < 0.05). Pure tone average implant aided thresholds (41 dB) were equivalent to that of walk-in-aided (37 dB) condition with no significant difference (p < 0.05) between patients’ walk-in-aided individual frequency thresholds and implant-aided thresholds. Word recognition scores and hearing in noise scores were similar between the walk-in-aided and for the implant-aided condition. Patient benefit scales will be presented at all end points. Conclusions Results of the Otologics MET Fully Implantable Hearing Device Phase II trial provide evidence that this fully implantable device is a viable alternative to currently available hearing aids in patients with sensorineural hearing loss.

Framingham risk score is associated with hearing outcomes in patients with idiopathic sudden sensorineural hearing loss

2020 ◽  
Vol 134 (5) ◽  
pp. 419-423
Author(s):  
Y-S Chang ◽  
S Park ◽  
M K Lee ◽  
Y C Rah ◽  
J Choi
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Risk Score ◽  
Pure Tone ◽  
Framingham Risk Score ◽  
Sudden Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Pure Tone Average ◽  
Framingham Risk ◽  
Group 1

AbstractObjectiveTo assess the Framingham risk score as a prognostic tool for idiopathic sudden sensorineural hearing loss patients.MethodsMedical records were reviewed for unilateral idiopathic sudden sensorineural hearing loss patients between January 2010 and October 2017. The 10-year risk of developing cardiovascular disease was calculated. Patients were subdivided into groups: group 1 – Framingham risk score of less than 10 per cent (n = 28); group 2 – score of 10 to less than 20 per cent (n = 6); and group 3 – score of 20 per cent or higher (n = 5).ResultsInitial pure tone average and Framingham risk score were not significantly associated (p = 0.32). Thirteen patients in group 1 recovered completely (46.4 per cent), but none in groups 2 and 3 showed complete recovery. Initial pure tone average and Framingham risk score were significantly associated in multivariable linear regression analysis (R2 = 0.36). The regression coefficient was 0.33 (p = 0.003) for initial pure tone average and −0.67 (p = 0.005) for Framingham risk score.ConclusionFramingham risk score may be useful in predicting outcomes for idiopathic sudden sensorineural hearing loss patients, as those with a higher score showed poorer hearing recovery.

Sudden sensorineural hearing loss in a patient with primary antiphospholipid syndrome

2007 ◽  
Vol 122 (2) ◽  
pp. 204-206 ◽  
Author(s):  
K-T Kang ◽  
Y-H Young
Keyword(s):  
Hearing Loss ◽  
Acetylsalicylic Acid ◽  
Sensorineural Hearing Loss ◽  
Antiphospholipid Syndrome ◽  
Pure Tone ◽  
Sudden Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Primary Antiphospholipid Syndrome ◽  
Pure Tone Average ◽  
The Right

AbstractObjective:Despite multiple systemic manifestations, sudden sensorineural hearing loss in a patient with antiphospholipid syndrome is rarely reported.Patient:A 46-year-old man with primary antiphospholipid syndrome had a sudden onset of hearing loss and tinnitus in the right ear in December 2005, because he discontinued use of warfarin and acetylsalicylic acid for a few days.Results:Audiometry revealed saucer-type sensorineural hearing loss with a pure tone average of 73 dB in the right ear, and flat-type hearing loss with a pure tone average of 25 dB in the left ear. Electronystagmography displayed multiple central signs and bilateral canal paresis, while a vestibular evoked myogenic potential test revealed bilateral delayed responses. After admission, the patient was re-treated with warfarin and acetylsalicylic acid. Follow-up audiometry showed recovery of right-sided hearing, with a pure tone average of 12 dB, three days after presentation.Conclusion:Consensus exists on the effectiveness of anticoagulant agents in aiding a favourable outcome of sudden sensorineural hearing loss in patients with antiphospholipid syndrome.

Histone acetylation in refractory sudden sensorineural hearing loss patients after intratympanic methylprednisolone perfusion

2019 ◽  
Vol 133 (10) ◽  
pp. 895-902 ◽  
Author(s):  
L Xie ◽  
J Hou ◽  
H Qi ◽  
Y Dai ◽  
W She
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Histone Acetylation ◽  
Therapeutic Effect ◽  
Pure Tone ◽  
Histone H3 ◽  
Sudden Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Average Gain ◽  
Pure Tone Average

AbstractObjectiveTo examine the relationship between the therapeutic effect of intratympanic methylprednisolone perfusion and histone acetylation in refractory sudden sensorineural hearing loss.MethodsThirty-four refractory sudden sensorineural hearing loss patients were enrolled and treated with intratympanic methylprednisolone perfusion. Pure tone average, acetylated histone H3, acetylated histone H4 and histone deacetylase 2 (HDAC2) were measured in peripheral blood mononuclear cells before and after intratympanic methylprednisolone perfusion. Sixteen healthy volunteers were recruited to obtain normal reference values.ResultsPure tone average in sudden sensorineural hearing loss patients improved from 84.14 ± 13.54 dB to 73.56 ± 18.45 dB after intratympanic methylprednisolone perfusion. Up-regulations in HDAC2 protein level, and down-regulations in histone H3 and H4 acetylation were observed in the intratympanic methylprednisolone perfusion sensitive group (pure tone average gain of 15 dB or more), while no significant changes were observed in the intratympanic methylprednisolone perfusion insensitive group (pure tone average gain of less than 15 dB).ConclusionIntratympanic methylprednisolone perfusion can improve hearing in a considerable number of refractory sudden sensorineural hearing loss patients. The therapeutic effect is closely related to reduced histone acetylation.

The Fate of the Non-Operated Ear in Otosclerosis

1989 ◽  
Vol 100 (3) ◽  
pp. 224-226 ◽  
Author(s):  
Rory Willis
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Hearing Aids ◽  
Bone Conduction ◽  
Sensorineural Hearing ◽  
The Other ◽  
High Tone ◽  
Term Benefit ◽  
Sensorineural Loss

Records of 300 consecutive patients who had only one ear operated on by stapedectomy and who received long-term followup were studied. These cases came from 3036 stapedectomy operations performed between January 1961 and April 1969. In general, the two ears behaved the same: If a “flat” sensorineural loss occurred in one ear, it was likely to develop in the other. Similarly, if one ear developed a high-tone loss, the other would do likewise. With the exception of acute fistula, there is no suggestion that the operation of stapedectomy predisposes an ear to late sensorineural problems. Patients with bone-conduction thresholds that are depressed at all frequencies when first examined should be advised that progressive sensorineural hearing loss may occur later in both ears. Accordingly, the benefit gained by stapedectomy may ultimately need to be supplemented by hearing aids. This study also revealed that a patient with clinical conductive otosclerosis in only one ear at first presentation had only a 50% chance of long-term benefit from stapedectomy.

Intratympanic steroid injection as a salvage treatment for sudden sensorineural hearing loss

2014 ◽  
Vol 128 (12) ◽  
pp. 1044-1049 ◽  
Author(s):  
S Belhassen ◽  
I Saliba
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Pure Tone ◽  
Sudden Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Discrimination Score ◽  
Speech Discrimination ◽  
Low Frequencies ◽  
Pure Tone Average ◽  
Speech Discrimination Score

AbstractObjective:To determine the efficacy of intratympanic methylprednisolone injections for treating sudden sensorineural hearing loss.Method:A retrospective chart review was performed to identify patients suffering from sudden sensorineural hearing loss with no recovery after oral steroids. Patients were given up to three intratympanic methylprednisolone injections at one-week intervals. They were classified according to their functional hearing class, remission was monitored and potential factors affecting prognosis were analysed.Results:Intratympanic injections provide effective salvage therapy for sudden sensorineural hearing loss (p = 0.039). Changes in pure tone average and speech discrimination score were analysed following intratympanic methylprednisolone injections. The pure tone average reached a plateau after the second injection; however, the speech discrimination score improved until after the third injection. Hearing improvement after intratympanic injections mainly occurred at low frequencies. The interval between symptoms appearing and intratympanic injections starting was not significantly associated with remission (p = 0.680).Conclusion:A delay between symptom onset and the first intratympanic methylprednisolone injection does not seem to affect prognosis.

Hearing recovery from deafness caused by bromate intoxication

2018 ◽  
Vol 132 (11) ◽  
pp. 1039-1041 ◽  
Author(s):  
J Suzuki ◽  
Y Takanashi ◽  
A Koyama ◽  
Y Katori
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Pure Tone ◽  
Pure Tone Audiometry ◽  
Auditory Brainstem ◽  
Sensorineural Hearing ◽  
Auditory Brainstem Responses ◽  
Common Symptom ◽  
Hearing Recovery ◽  
Continuous Haemodiafiltration

AbstractObjectivesSodium bromate is a strong oxidant, and bromate intoxication can cause irreversible severe-to-profound sensorineural hearing loss. This paper reports the first case in the English literature of bromate-induced hearing loss with hearing recovery measured by formal audiological assessment.Case reportA 72-year-old woman was admitted to hospital with complaints of profound hearing loss, nausea, diarrhoea and anuria after bromate ingestion in a suicide attempt. On admission, pure tone audiometry and auditory brainstem responses showed profound bilateral deafness. Under the diagnosis of bromate-induced acute renal failure and sensorineural hearing loss, continuous haemodiafiltration was performed. When dialysis was discontinued, pure tone audiometry and auditory brainstem responses showed partial threshold recovery from profound deafness.ConclusionSevere-to-profound sensorineural hearing loss is a common symptom of bromate intoxication. Bromate-induced hearing loss may be partially treated, and early application of continuous haemodiafiltration might be useful as a treatment for this intractable condition.

Sign in / Sign up

Export Citation Format

Share Document